Nycomed rumours fly as Takeda braces itself for a post-Actos world
This article was originally published in Scrip
Executive Summary
Faced with a looming patent cliff for its top product Actos (pioglitazone) from August next year, Takeda is taking a three-pronged strategy to deal with the challenge.